CAMBRIDGE, Mass., March 3 /PRNewswire/ -- ETEX Corporation, an advanced biomaterials company, announced today that it has entered into a supply agreement with LifeNet Health, Inc.
Under the agreement, LifeNet Health will provide ETEX with Demineralized Bone Matrix (DBM) powder to be mixed with ETEX's proprietary calcium phosphate to form a bone graft substitute material called EquivaBone(TM). ETEX will manufacture EquivaBone(TM) in its Cambridge facilities and market the product through its newly formed direct distribution channel.
EquivaBone(TM) combines the osteoinductive properties of DBM with the fast setting and osteoconductive properties of synthetic calcium phosphate. Unlike other DBM products on the market, EquivaBone(TM) flows and sets hard with structural integrity.
Brian Ennis, CEO of ETEX Corporation, states "ETEX is excited to offer surgeons an osteoinductive bone graft material with enhanced performance and handling characteristics. We are proud and privileged to work with LifeNet Health, Inc, one of the premier tissue banks in the country."
The EquivaBone(TM) launch follows the recent introduction of Beta-bsm(TM), an injectable bone substitute material, and Gamma-bsm(TM), a moldable putty.
Doug Wilson, Executive Vice President of LifeNet Health, states "We are pleased to announce our relationship with ETEX Corporation, and are proud to make invaluable DBM available for surgeons to help patients. We continue to be committed to saving lives and restoring health."
About ETEX Corporation
Established in 1989, ETEX Corporation develops, manufactures and
commercializes calcium phosphate-based biomaterials for improved orthopedic
clinical outcomes. A leader in bioresorbable bone substitute materials,
ETEX focuses on expanding applications through combinations with cells,
biologics, or therapeutic agents delivered in minimally invasive and easy
to use systems. For more information, visit
|SOURCE ETEX Corporation|
Copyright©2008 PR Newswire.
All rights reserved